Skip to Content
Merck

R9281

Rotigotine hydrochloride

≥98% (HPLC)

Synonym(s):

(−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H25NOS·HCl
CAS Number:
125572-93-2
Molecular Weight:
351.93
NACRES:
NA.77
PubChem Substance ID:
329824046
UNSPSC Code:
12352200
MDL number:
MFCD00906149
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
desiccated

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1

SMILES string

Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2

InChI key

CEXBONHIOKGWNU-NTISSMGPSA-N

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to off-white

solubility

DMSO: >10 mg/mL

originator

UCB Inc.

storage temp.

room temp

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000140733
0000085433
0000026628
0000026629
0000025067

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Aiping Wang et al.
Pharmaceutical research, 29(9), 2367-2376 (2012-05-03)
To prepare rotigotine loaded microspheres (RoMS) to achieve continuous dopaminergic stimulation (CDS) for the treatment of Parkinson's disease (PD) and investigate both the therapeutic benefit and inducibility of AIMs of administration of RoMS combination with L-DOPA in 6-OHDA-leisioned rats. Rotigotine
Naoki Adachi et al.
Neuroscience letters, 662, 44-50 (2017-10-11)
Brain-derived neurotrophic factor (BDNF) critically controls the fate and function of the neuronal network and has received much attention as a target of many brain diseases. Dopaminergic system dysfunction has also been implicated in a variety of neuropsychiatric diseases. Rotigotine
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
Poewe W H, et al.
Lancet Neurology, 6(6), 513-520 (2007)
Heike Beneš et al.
Sleep medicine, 13(6), 589-597 (2012-04-17)
To assess the risk of augmentation under treatment with the transdermally delivered dopamine agonist rotigotine for restless legs syndrome (RLS). Experts in RLS augmentation retrospectively reviewed data from two double-blind, placebo-controlled 6-month trials (745 rotigotine and 214 placebo subjects, NCT00136045
Fabienne Stephanie Sprenger et al.
Expert opinion on drug safety, 11(3), 503-512 (2012-04-04)
Rotigotine, a non-ergolinic dopamine-receptor agonist, is currently approved as monotherapy in early idiopathic Parkinson's disease (IPD), in moderate to severe idiopathic restless legs syndrome (RLS) and as adjunct therapy to levodopa in advanced IPD. Randomized, double-blind, placebo-controlled, as well as
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service